IMBdx 2026 Q1: Revenue +27%, Operating Loss Narrows, Net Loss Widens

2026 Q1 revenue 1.27B KRW (same period prior year 1.00B, +27%)
Operating loss 2.46B KRW (prior year 3.73B, loss narrowed 34%)
Net loss 2.25B KRW (prior year 1.77B, net loss increased 27%)
Cash & cash equivalents 2.0B KRW, short-term financial assets 17.6B KRW
Debt ratio 9%, sound financial structure
Core products: AlphaLiquid®100/HRR (profiling), CancerDetect (MRD), CancerFind (screening)
CancerDetect received innovative medical technology approval in 2025 (for colorectal cancer)
R&D: 33 ongoing projects (including multi-cancer early detection)
Top 3 customers account for 60% of revenue (customer concentration risk)
Foreign exchange risk: 10% change in USD/JPY impacts ~0.45B KRW